Puma Biotechnology News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.12.19	plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer (Businesswire)
12.12.19	GILD's KTE-X19 To Face FDA, NTEC Drops As NVS Walks Away, KZIA On Watch (RTTNews)
12.12.19	Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium (Businesswire)
02.12.19	Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries (Businesswire)
06.11.19	Puma Biotechnology Reports Third Quarter 2019 Financial Results (Businesswire)
04.11.19	Puma Biotechnology to Present at the Credit Suisse Healthcare Conference (Businesswire)
23.10.19	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
03.10.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.10.19	FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer (Businesswire)
25.09.19	Puma Biotechnology to Present at Cantor Global Healthcare Conference (Businesswire)
11.09.19	Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
05.09.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.09.19	Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference (Businesswire)
03.09.19	FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases (Businesswire)
08.08.19	Puma Biotechnology Reports Second Quarter 2019 Financial Results (Businesswire)
06.08.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
25.07.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
24.07.19	Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results (Businesswire)
03.07.19	Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019 (Businesswire)
01.07.19	Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
05.06.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.06.19	Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting (Businesswire)
02.06.19	Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting (Businesswire)
29.05.19	Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference (Businesswire)
09.05.19	Puma Biotechnology Reports First Quarter 2019 Financial Results (Businesswire)
08.05.19	Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019 (Businesswire)
25.04.19	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (Businesswire)
09.04.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.04.19	Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations (Businesswire)
02.04.19	Puma Biotechnology und Pierre Fabre schliessen exklusiven Lizenzvertrag zur Entwicklung und Vermarktung von NERLYNX® (Neratinib) in Europa ab (Businesswire)
01.04.19	Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe (Businesswire)
28.03.19	Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 (Businesswire)
14.03.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.03.19	Puma Biotechnology to Present at Cowen’s Annual Health Care Conference (Businesswire)
28.02.19	Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results (Businesswire)
15.02.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
13.02.19	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results (Businesswire)
05.02.19	Puma Biotechnology Announces Litigation Victory with Jury’s Decision (Businesswire)
11.01.19	Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada (Businesswire)
03.01.19	Puma Biotechnology to Present at J. P. Morgan Healthcare Conference (Businesswire)
02.01.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
17.12.18	Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer (Businesswire)
11.12.18	Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
10.12.18	Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.12.18	Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium (Businesswire)
03.12.18	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.11.18	Puma Biotechnology to Present at Credit Suisse Healthcare Conference (Businesswire)
06.11.18	TRPX On A High, PBYI Braces For Busy Times Ahead, NVCN On Watch (RTTNews)
01.11.18	Puma Biotechnology Reports Third Quarter 2018 Financial Results (Businesswire)
18.10.18	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Puma Biotechnology Inc

Aktien Top/Flop

Meistgelesene Nachrichten